Tag: FabiFlu
Glenmark introduces higher strength (400 mg) of FabiFlu
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it would introduce a 400 mg version of oral antiviral FabiFlu to treat mild...
Glenmark reduces price of oral antiviral FabiFlu by 27 % to...
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely...
Glenmark gets nod from DCGI for Favipiravir launch
In a landmark development for Covid-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced the launch of antiviral drug Favipiravir...